Oyster Point Pharma: Termination Of A Material Definitive Agreement. The Original Form 8k Stated That The Aggregate Payoff Amount For The Credit Agreement And Guaranty, Dated As Of August 5, 2021, By And Among Oyster Point, The Subsidiary Guarantors Party Thereto, The Lenders Party Thereto And Orbimed Royalty & Credit Opportunities Iii, Lp (as Amended From Time To Time, The Orbimed Credit Agreement ) Was Approximately $298.8 Million. This Amendment Corrects Such Mistake By Amending And Restating Item 1.02 Of The Original Form 8k To Clarify That The Aggregate Payoff Amount For The Orbimed Credit Agreement Was Approximately $112.2 Million. Except For This Typographical Mistake Described Above, This Amendment Does Not Modify Or Update Any Of The Other Information Set Forth In The Original Form 8k, Completion Of Acquisition Or Disposition Of Assets, Notice Of Delisting Or Failure To Satisfy A Continuing Listing Rule Or Standard; Transfer Of Listing, Material Modification To Rights Of Security Holders, Changes In Control Of Registrant, Departure Of Directors Or Certain Officers; Election Of Directors; Appointment Of Certain Officers; Compensatory Arrangements Of Certain Officers, Amendments To Articles Of Incorporation Or Bylaws; Change In Fiscal Year, Financial Statements And Exhibits

Show full article

This functionality is available for registred users only

• Full name
  Oyster Point Pharma, Inc.
• Registration country
  USA
• Industry
  Pharmaceutical Preparation and Biotechnology
• М/S&P/F
  *** / *** / ***